The ERK inhibitor ulixertinib shows early efficacy in treating tumors with MAPK pathway alterations, prevalent in 30% of all human cancers due to activating mutations in RAS, BRAF, or MAP2K1 (MEK1) [61, 62]. The gene discussed is MAP2K1; the disease is cancer.